vs
Side-by-side financial comparison of ALPHA PRO TECH LTD (APT) and Sanara MedTech Inc. (SMTI). Click either name above to swap in a different company.
Sanara MedTech Inc. is the larger business by last-quarter revenue ($27.5M vs $13.9M, roughly 2.0× ALPHA PRO TECH LTD). ALPHA PRO TECH LTD runs the higher net margin — 5.0% vs -5.9%, a 10.9% gap on every dollar of revenue. On growth, Sanara MedTech Inc. posted the faster year-over-year revenue change (4.6% vs 0.3%). Sanara MedTech Inc. produced more free cash flow last quarter ($3.9M vs $51.0K). Over the past eight quarters, Sanara MedTech Inc.'s revenue compounded faster (21.8% CAGR vs 1.4%).
Alpha Pro Tech Ltd is a leading developer, manufacturer and marketer of disposable protective apparel, face masks, and building supply products including weather-resistant barriers. It primarily serves the healthcare, industrial, and construction sectors, with core operating markets concentrated in North America.
Sanara MedTech Inc. is a US-based medical technology company that develops, manufactures, and distributes innovative surgical, wound care, and post-acute rehabilitation products. It mainly serves healthcare providers, hospitals, and long-term care facilities across North America, with a portfolio of FDA-cleared solutions designed to improve patient outcomes and lower clinical care operational costs.
APT vs SMTI — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $13.9M | $27.5M |
| Net Profit | $698.0K | $-1.6M |
| Gross Margin | 37.1% | 93.2% |
| Operating Margin | 6.9% | 23.5% |
| Net Margin | 5.0% | -5.9% |
| Revenue YoY | 0.3% | 4.6% |
| Net Profit YoY | -17.6% | 5.3% |
| EPS (diluted) | $0.06 | $-0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $13.9M | $27.5M | ||
| Q3 25 | $14.8M | $26.3M | ||
| Q2 25 | $16.7M | $25.8M | ||
| Q1 25 | $13.8M | $23.4M | ||
| Q4 24 | $13.8M | $26.3M | ||
| Q3 24 | $14.3M | $21.7M | ||
| Q2 24 | $16.3M | $20.2M | ||
| Q1 24 | $13.5M | $18.5M |
| Q4 25 | $698.0K | $-1.6M | ||
| Q3 25 | $976.0K | $-30.4M | ||
| Q2 25 | $1.2M | $-2.0M | ||
| Q1 25 | $613.0K | $-3.5M | ||
| Q4 24 | $847.0K | $-1.7M | ||
| Q3 24 | $862.0K | $-2.9M | ||
| Q2 24 | $1.6M | $-3.5M | ||
| Q1 24 | $576.0K | $-1.8M |
| Q4 25 | 37.1% | 93.2% | ||
| Q3 25 | 39.7% | 92.9% | ||
| Q2 25 | 36.8% | 92.5% | ||
| Q1 25 | 39.0% | 92.2% | ||
| Q4 24 | 37.6% | 91.4% | ||
| Q3 24 | 38.5% | 90.8% | ||
| Q2 24 | 42.0% | 90.0% | ||
| Q1 24 | 40.2% | 89.8% |
| Q4 25 | 6.9% | 23.5% | ||
| Q3 25 | 7.4% | 11.2% | ||
| Q2 25 | 8.0% | -0.1% | ||
| Q1 25 | 3.3% | -8.9% | ||
| Q4 24 | 4.9% | 18.6% | ||
| Q3 24 | 5.2% | 3.6% | ||
| Q2 24 | 10.5% | -14.3% | ||
| Q1 24 | 2.4% | -8.3% |
| Q4 25 | 5.0% | -5.9% | ||
| Q3 25 | 6.6% | -115.5% | ||
| Q2 25 | 7.5% | -7.8% | ||
| Q1 25 | 4.4% | -15.1% | ||
| Q4 24 | 6.1% | -6.5% | ||
| Q3 24 | 6.0% | -13.2% | ||
| Q2 24 | 10.1% | -17.4% | ||
| Q1 24 | 4.3% | -9.5% |
| Q4 25 | $0.06 | $-0.32 | ||
| Q3 25 | $0.09 | $-3.40 | ||
| Q2 25 | $0.12 | $-0.23 | ||
| Q1 25 | $0.06 | $-0.41 | ||
| Q4 24 | $0.07 | $-0.18 | ||
| Q3 24 | $0.08 | $-0.34 | ||
| Q2 24 | $0.15 | $-0.41 | ||
| Q1 24 | $0.05 | $-0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $17.0M | $16.6M |
| Total DebtLower is stronger | — | $46.0M |
| Stockholders' EquityBook value | $62.5M | $5.9M |
| Total Assets | $74.1M | $72.9M |
| Debt / EquityLower = less leverage | — | 7.74× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $17.0M | $16.6M | ||
| Q3 25 | $17.7M | $14.9M | ||
| Q2 25 | $14.5M | $17.0M | ||
| Q1 25 | $13.4M | $20.7M | ||
| Q4 24 | $18.6M | $15.9M | ||
| Q3 24 | $18.4M | $16.3M | ||
| Q2 24 | $16.2M | $6.2M | ||
| Q1 24 | $18.5M | $2.8M |
| Q4 25 | — | $46.0M | ||
| Q3 25 | — | $45.1M | ||
| Q2 25 | — | $44.2M | ||
| Q1 25 | — | $43.4M | ||
| Q4 24 | — | $30.7M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $14.4M | ||
| Q1 24 | — | $9.7M |
| Q4 25 | $62.5M | $5.9M | ||
| Q3 25 | $62.5M | $6.1M | ||
| Q2 25 | $62.2M | $35.4M | ||
| Q1 25 | $61.7M | $36.7M | ||
| Q4 24 | $62.2M | $39.4M | ||
| Q3 24 | $62.1M | $39.8M | ||
| Q2 24 | $62.0M | $41.7M | ||
| Q1 24 | $61.6M | $43.3M |
| Q4 25 | $74.1M | $72.9M | ||
| Q3 25 | $73.9M | $71.1M | ||
| Q2 25 | $73.2M | $98.8M | ||
| Q1 25 | $72.2M | $96.4M | ||
| Q4 24 | $73.7M | $88.1M | ||
| Q3 24 | $73.3M | $88.5M | ||
| Q2 24 | $72.7M | $73.4M | ||
| Q1 24 | $72.7M | $70.9M |
| Q4 25 | — | 7.74× | ||
| Q3 25 | — | 7.33× | ||
| Q2 25 | — | 1.25× | ||
| Q1 25 | — | 1.18× | ||
| Q4 24 | — | 0.78× | ||
| Q3 24 | — | 0.76× | ||
| Q2 24 | — | 0.34× | ||
| Q1 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $318.0K | $3.9M |
| Free Cash FlowOCF − Capex | $51.0K | $3.9M |
| FCF MarginFCF / Revenue | 0.4% | 14.0% |
| Capex IntensityCapex / Revenue | 1.9% | 0.3% |
| Cash ConversionOCF / Net Profit | 0.46× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.7M | $2.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $318.0K | $3.9M | ||
| Q3 25 | $3.9M | $2.2M | ||
| Q2 25 | $2.1M | $2.7M | ||
| Q1 25 | $-4.0M | $-2.0M | ||
| Q4 24 | $2.4M | $932.0K | ||
| Q3 24 | $5.3M | $2.1M | ||
| Q2 24 | $-873.0K | $-1.4M | ||
| Q1 24 | $-1.2M | $-1.6M |
| Q4 25 | $51.0K | $3.9M | ||
| Q3 25 | $3.8M | $1.1M | ||
| Q2 25 | $1.9M | $902.7K | ||
| Q1 25 | $-4.1M | $-3.7M | ||
| Q4 24 | $970.0K | $859.9K | ||
| Q3 24 | $3.2M | $2.0M | ||
| Q2 24 | $-1.0M | $-1.5M | ||
| Q1 24 | $-1.3M | $-1.7M |
| Q4 25 | 0.4% | 14.0% | ||
| Q3 25 | 25.9% | 4.2% | ||
| Q2 25 | 11.7% | 3.5% | ||
| Q1 25 | -29.6% | -15.9% | ||
| Q4 24 | 7.0% | 3.3% | ||
| Q3 24 | 22.3% | 9.4% | ||
| Q2 24 | -6.2% | -7.3% | ||
| Q1 24 | -9.3% | -9.0% |
| Q4 25 | 1.9% | 0.3% | ||
| Q3 25 | 0.7% | 4.0% | ||
| Q2 25 | 0.8% | 6.8% | ||
| Q1 25 | 1.0% | 7.4% | ||
| Q4 24 | 10.4% | 0.3% | ||
| Q3 24 | 15.1% | 0.0% | ||
| Q2 24 | 0.8% | 0.3% | ||
| Q1 24 | 0.6% | 0.4% |
| Q4 25 | 0.46× | — | ||
| Q3 25 | 4.02× | — | ||
| Q2 25 | 1.68× | — | ||
| Q1 25 | -6.46× | — | ||
| Q4 24 | 2.85× | — | ||
| Q3 24 | 6.18× | — | ||
| Q2 24 | -0.53× | — | ||
| Q1 24 | -2.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APT
Segment breakdown not available.
SMTI
| Soft Tissue Repair Products | $24.7M | 90% |
| Bone Fusion Products | $2.8M | 10% |
